December 27, 2014 8:42 AM ET


Company Overview of AnaptysBio, Inc.

Company Overview

AnaptysBio, Inc. focuses on the generation of antibody therapeutics, as well as on the use of somatic hypermutation (SHM) for antibody discovery and optimization. The company’s SHM-XEL platform couples human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies that replicates key features of the human immune system. It develops ANB020Its, an anti-IL-33 lead candidate antibody that inhibits IL-33 cytokine function by blocking interaction with receptor at low picomolar potency; a portfolio of antibodies for immuno-oncology to modulate the function of T cell negative regulators, including PD-1, TIM-3, and LAG-3; ANB012, an anti-ActRIIb a...

10421 Pacific Center Court

Suite 200

San Diego, CA 92121

United States

Founded in 2005





Key Executives for AnaptysBio, Inc.

Chief Executive Officer
Executive Chair
Age: 49
Chief Development Officer
Age: 57
Director of Cell Biology
Compensation as of Fiscal Year 2014.

AnaptysBio, Inc. Key Developments

TESARO and AnaptysBio Expand Immuno-Oncology Collaboration to Include Novel Bispecific Antibody Candidate

TESARO, Inc. and AnaptysBio, Inc. announced an expansion of their immuno-oncology collaboration and exclusive license agreement to include development of a novel bispecific antibody candidate designed to target two undisclosed immune checkpoints. Under the terms of this expansion, TESARO will pay AnaptysBio an undisclosed upfront fee and will provide funding for all costs incurred by AnaptysBio related to the development of a clinical antibody candidate. For each program within the collaboration, AnaptysBio is eligible to receive milestone payments if certain research and development events are achieved and additional payments for achievement of certain U.S. and ex-U.S. regulatory submissions and approvals in multiple indications. AnaptysBio will also be eligible to receive royalties related to worldwide net sales of products developed under the collaboration, and may earn certain commercial milestone payments if specified levels of annual worldwide net sales are attained. AnaptysBio and TESARO will together complete preclinical development of the antibody candidates, with TESARO being solely responsible for all clinical development, manufacturing, regulatory and commercial activities.

AnaptysBio, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 01:30 PM

AnaptysBio, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 01:30 PM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Hamza Suria, Chief Executive Officer, President and Director.

AnaptysBio, Inc. Appoints Marco Londei as Chief Development Officer

AnaptysBio, Inc. announced the appointment of Marco Londei, M.D. as Chief Development Officer. Dr. Londei will lead the preclinical and clinical development of AnaptysBio's proprietary antibody pipeline. Dr. Londei joins AnaptysBio from Bristol-Myers Squibb (BMS) where he was Therapeutic Area Head, Immunosciences and responsible for early clinical and translational research for a portfolio of immune-related therapeutics.

Similar Private Companies By Industry

Company Name Region
Mountain View Pharmaceuticals, Inc. United States
Neurona Therapeutics Inc. United States
Affomix Corporation United States
Satoris, Inc. United States
Leonard-Meron Biosciences, Inc. United States

Recent Private Companies Transactions

March 13, 2014
AnaptysBio, Inc., Worldwide Rights to TIM-3, LAG-3 and PD-1 Targeting Products

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AnaptysBio, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at